Key result
Pre-stroke GLP-1 RA use is linked to reduced post-stroke mortality and dementia in type 2 diabetes.
Why the study?
Does starting GLP-1 RAs within 6 months before a stroke reduce post-stroke mortality and dementia in Type 2 Diabetes patients?
Does starting GLP-1 RAs within 6 months before a stroke reduce post-stroke mortality and dementia in Type 2 Diabetes patients?
Matched cohort study examines the effect of GLP-1 receptor agonists on post-stroke outcomes in T2D patients, suggesting significant benefits.
The goal of this study is to test the neuroprotective effects of starting Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) within 6 months before a stroke in Type 2 Diabetes (T2D) patients
No takes yet. Share an insight, caveat, or question.
abduljabbar et al. (2026) studied this question. GLP-1 receptor agonist use within 6 months before a stroke is associated with reduced post-stroke mortality and dementia in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: